NCT06543056View on ClinicalTrials.gov

A Study of ES014 in Subjects With Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

ES014

ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Elpiscience (Suzhou) Biopharma, Ltd.

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER